2022 Revenues ($USD) : $294,011,000
2022 R&D spend : $100,999,000
2022 Number of Employees : 727
Fiscal Year End : 12/31/2021
Company CEO : Thomas Burns, president and CEO

Founded in 1998, Glaukos focuses on treating ophthalmic diseases. The company has both medical device and pharmaceutical operations. In August, the company announced that its second-quarter results missed the consensus earnings forecast. In an earnings call, Glaukos Chair and CEO Thomas Burns signaled that the company is gearing up for several product launches. Burns also noted that it continues to invest in its pipeline of platform technologies for chronic eye diseases. Glaukos anticipates full-year 2022 net sales in the range of $275 million to $280 million. Earlier in 2022, Glaukos announced plans to make several changes to its upper ranks. –BB